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Abstract
The CHA2DS2-VASc scale is commonly used to assess the risk of thromboembolism in patients with atrial fibrillation (AF). 
Oral anticoagulants are recommended for the prevention of stroke in patients with AF with a CHA2DS2-VASc score of ≥ 2 
for men and ≥ 3 for women. There are known factors that have not been included in this scale, but they significantly 
increase the risk of thromboembolism. Not all patients with AF who are at high risk of thromboembolism receive anti-
coagulation therapy. This is mainly due to the contraindications to the use of drugs from this group.
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Introduction
Patients with atrial fibrillation (AF) are at significantly incre-
ased risk of thromboembolic complications. The presence 
of AF increases the risk of stroke by 5 times, and every 5th 
stroke can be attributed to this arrhythmia [1]. The risk of 
complications can be significantly reduced by the use of 
oral anticoagulants (OACs). Prophylaxis of thromboembolic 
complications depends on the risk of thromboembolism as-
sessed using the CHA2DS2-VASc score. Oral anticoagulants 
are recommended for the prevention of stroke in patients 
with AF with a CHA2DS2-VASc score of 2 or more in men and 
3 or more in women [2]. Prophylactic anticoagulation has 
been shown to be associated with a 60–70% reduction in 
the risk of thromboembolic complications and mortality [3].
Non-classical risk factors  
for thromboembolic complications  
in patients with AF
The guidelines of the European Society of Cardiology (ESC) 
recommend the use of the CHA2DS2-VASc score (Table 1) 
in the assessment of thromboembolic risk in patients with 
AF [2]. In 2020, a different risk score for the assessment 
of thromboembolic complications was also proposed — the 
ABC scale, which includes: age, biomarkers and clinical 
history [4]. The CHA2DS2-VASc and ABC scores have the 
highest predictive value in predicting thromboembolic risk 
in patients with AF. According to the 2020 ESC guidelines, 
the CHA2D2-VASc score should be used to assess the risk 
of thromboembolism and to qualify patients for anticoa-
gulation treatment.
However, there are other factors known that are not in-
cluded in the CHA2DS2-VASc score, but significantly increase 
the risk of thromboembolism. These factors include, but 
are not limited to, the type of AF, chronic kidney disease, 
and cancer. Piccini et al. [5] proved that in patients with 
non-valvular AF with a moderate to high risk of stroke, re-
nal dysfunction is a strong predictor of stroke and syste-
mic embolism, and concluded that the assessment of renal 
function should be included in the stratification of stroke 
risk in patients with AF. In the proposed R2CHADS2 score, 
2 points were added to the CHADS2 score if the creatinine 
clearance (CrCl) was below 60 mL/min. Decreased CrCl 
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was a strong independent prognostic factor for stroke and 
systemic embolism; and was only surpassed by a previo-
us stroke or transient ischemic attack. According to the 
R2CHADS2 score, the reclassification rate increased by 
6.2% compared to CHA2DS2-VASc and by 8.2% compared 
to CHADS2. It can therefore be concluded that there is an 
independent association between renal impairment and 
an increased risk of stroke in patients with AF.
The relationship between the type of AF and stroke risk 
remains controversial. The CODE-AF registry has shown that 
paroxysmal AF may be associated with a lower incidence 
of stroke compared with non-paroxysmal AF. This was pro-
bably due to the fact that patients with persistent and per-
manent AF were older, had more comorbidities, and were 
prescribed anticoagulants much more often than patients 
with paroxysmal AF [6].
Many clinical risk factors for stroke, such as obstructive 
sleep apnea (OSA), are closely related to the components 
of the CHA2DS2-VASc, but taking them into account does 
not improve its predictive value. The relationship between 
smoking or obesity and the risk of stroke in patients with AF 
is still controversial [7]. Overweight and obesity have been 
shown to be risk factors for ischemic stroke, thromboem-
bolism and death in patients with AF. Various biomarkers, 
such as troponin, natriuretic peptides, and von Willebrand 
coefficient, have shown predictive value in the assessment 
of stroke risk in AF patients treated with OACs [8, 9]. The 
level of the N-terminal pro-B-type natriuretic peptide (NT-
-proBNP) was significantly associated with the risk of throm-
boembolic events and cardiovascular mortality.
Table 1. Components of the CHA2DS2-VASc score (source [2])
Risk factors and definition Score Definition
C Congestive HF, symptomatic HF, 
moderate to severe LV dysfunction 
or HCM
1 Recent decompensated HF regardless of LVEF (HFrEF or HFpEF) or the presen-
ce (even asymptomatic) of moderate to severe LV systolic dysfunction in cardiac 
imaging
H Hypertension 1 Resting blood pressure > 140/90 mm Hg in ≥ 2 measurements on different 
occasions or antihypertensive treatment
A Age ≥ 75 years 2 2 points assigned for the age of > 75 years
D Diabetes 1 Random venous blood glucose ≥ 200 mg/dL (≥ 11.1 mmol/L) + symptoms
Two fasting blood glucose measurements ≥ 126 mg/dL (≥ 7.0 mmol/L)
OGTT ≥ 200 mg/dL (≥ 11.1 mmol/L)
S Stroke/TIA/thromboembolism 2 History of stroke, systemic embolism or TIA
V Vascular disease 1 Vascular disease defined as a history of myocardial infarction, atherosclerotic 
peripheral artery disease, atherosclerotic plaque in the aorta
A Age of 65–74 years 1 1 point assigned for the age of 65–74 tears
Sc Sex category, female 1 Increases the risk in the presence of ≥ 1 other risk factor
Maximum score 9
HF — heart failure; LV — left ventricle; HCM — hypertrophic cardiomyopathy; LVEF — left ventricular ejection fraction; HFrEF — heart failure with reduced ejection fraction; HFpEF — heart failure with preserved 
ejection fraction; OGTT — oral glucose tolerance test; TIA — transient ischemic attack
In addition, elevated levels of inflammatory markers 
such as interleukin 6 (IL-6) and C-reactive protein (CRP) 
are reported to be associated with greater difficulty in ma-
intaining sinus rhythm and with increased risk of cardio-
vascular events and AF mortality. It has also been shown 
that the concentration of D-dimer may be associated with 
the risk of stroke in AF. Anticoagulation treatment reduces 
the concentration of this biomarker in the majority of tre-
ated patients [8].
Echocardiographic parameters are also among the risk 
factors for thromboembolism in patients with AF. It has 
been reported that left ventricular systolic dysfunction as-
sessed by transthoracic echocardiography may be a strong 
and independent prognostic factor for stroke in patients 
with AF. In contrast, left atrial diameter and mitral regur-
gitation are not associated with a higher risk of thrombo-
embolic events in patients with AF [10]. Table 2 lists risk 
factors that are significant in the stratification of the risk 
of stroke and other thromboembolic complications, but are 
not included in the CHA2DS2-VASc score.
Recommendations for thromboembolism 
prophylaxis in patients with AF at high risk 
of thromboembolic complications
Anticoagulation therapy is recommended in all patients 
with AF. Due to the fact that OACs significantly reduce the 
risk of stroke and mortality, the 2020 guidelines recom-
mend considering the inclusion of OAC also in patients with 
CHA2DS2-VASc score of 1 point (non-gender related), i.e. in 
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patients with an intermediate risk of thromboembolism [2]. 
High-risk patients with AF absolutely require OAC therapy. 
They are in a group particularly at risk of thromboembolic 
complications. It should also be mentioned that antiplatelet 
drugs cannot be used in the prophylaxis of thromboembolic 
complications in patients with AF [2].
In line with guidelines that have changed in recent ye-
ars, patients at high risk of stroke have always required 
anticoagulation therapy. The 2010 guidelines recommen-
ded that obtaining at least 2 points in the CHADS2 scale 
was an indication for the use of a vitamin K antagonist 
(VKA, vitamin K antagonist), 1 point allowed the choice be-
tween VKA and acetylsalicylic acid (ASA), while obtaining 
0 points meant that there are no indications for anticoa-
gulant treatment [14]. Guidelines, which have changed in 
recent years, have always indicated that patients at high 
risk of stroke required anticoagulation therapy. The guide-
lines from 2010 recommended that the CHADS2 score of 
at least 2 was an indication for the use of a vitamin K an-
tagonist (VKA), 1 point allowed the choice between VKA 
and acetylsalicylic acid (ASA), while obtaining 0 points in-
dicated that there were no indications for anticoagulant 
treatment [14]. For the first time, attention was drawn to 
the possibility of using two groups of novel OACs (NOACs) — 
direct thrombin inhibitors (e.g. dabigatran) and oral factor 
Xa inhibitors (e.g. rivaroxaban) — as part of antithrombotic 
prevention in patients with AF. In 2012, the update of the 
2010 guidelines was released; further evidence has emer-
ged in favor of the new OACs [15]. It has been proven that 
ASA in the prevention of stroke may be harmful and there is 
no evidence confirming its effectiveness in the prevention 
of thromboembolic complications in patients with AF [16]. 
In the following years, studies were conducted that asses-
sed OAC in patients with AF. They included mainly people 
at high risk of stroke [17, 18]. Men with a CHA2DS2-VASc 
score of at least 2 points and women with a score of 3 have 
been shown to benefit from OAC. Vitamin K antagonists and 
NOACs have been found to be effective in the prevention 
of stroke in patients with AF and to be safe for use [19]. 
The 2020 ESC Guidelines [2] once again provide strong 
evidence for the efficacy and safety of NOACs, the role of 
which has been significantly strengthened. Due to their ef-
fectiveness, safety profile and convenience of use, they are 
the drugs of first choice among OACs in the prevention of 
stroke in patients with AF, which is confirmed by large re-
gisters from recent years [20].
Prophylaxis of thromboembolic  
complications in large registries
With new guidelines and research in AF, the approach 
to using oral anticoagulants has evolved. It is absolutely 
indicated in patients at high risk of thromboembolism. It 
should be noted that the use of OACs in daily practice has 
increased in recent years. According to the data from the 
registry of Ding et al. [21], in 2001–2004, OACs were used 
in only 23% of patients with a CHA2DS2-VAS score of at least 
2 points while in 2012–2016 these drugs were used in as 
much as 84.3% of such patients in the study performed 
by Cools et al. [22], which is similar to the data from the 
EORP-AF [23] and PREFER in AF [24] registers. The results 
presented by Cowan et al. [25] and Holt et al. [26] are si-
milar and concern a specific time periods, i.e. 2009–2012 
and 2007–2010, respectively, in which the use of OAC 
was 55% and 53%. The GLORIA-AF II registry [27] shows 
a significant use of OACs in high-risk patients (83.2%), 
which contrasts with the results of phase I trial, in which 
ASA was most frequently prescribed. In the GARFIELD-AF 
and ORBIT-AF II registries, the use of OACs was 69% and 
87%, respectively, in patients with a CHA2DS2-VASc score of 
at least 2 points, but with significant geographical hetero-
geneity [ranges of 31–93% (GARFIELD-AF) and 66–100% 
(ORBIT-AF II)] In patients with newly diagnosed AF, the use 
of non-vitamin K antagonist oral anticoagulants increased 
over time to 43% in 2016 for GARFIELD-AF and 71% for 
ORBIT-AF II, while antiplatelet monotherapy decreased from 
Table 2. Stroke risk factors not included in the CHA2DS2-VASc score in patients with atrial fibrillation (AF) (based on [10–13])
Echocardiographic parameters Coagulation marker Biomarkers Others
LAV, LAVI D-dimers BNP CKD
LVEF Fibrinogen CRP Neoplastic disease
Atherosclerotic plaque in the aorta PAI-1 IL-6 LAA fibrosis (MRI)
LAA dysfunction TAT Cardiac troponins T and I AF type






LAV — left atrium volume; LAVI — left atrium volume index; LVEF — left ventricular ejection fraction; LAA — left atrial appendage; TOE — transechophageal echocardiography; CT — computed tomography;  
MRI — magnetic resonance imaging; TAT — thrombin–antithrombin III complex; PAI-1 — plasminogen activator inhibitor 1; BNP — B-type natriuretic peptide; CRP — C-reactive protein; IL-6 — interleukin 6;  
CKD — chronic kidney disease
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36% to 17% (GARFIELD-AF) and from 18% to 8% (ORBIT-
-AF I and II) [20]. Table 3 [20–32] presents the results 
of anticoagulation in the prevention of thromboembolic 
complications in patients with AF and high risk of stroke 
in individual registries. 
Limitations of anticoagulation in patients 
at high risk of thromboembolism
Restrictions on the use of OACs in patients at high risk 
of thromboembolism mainly concern contraindications 
to the use of drugs from this group. It is estimated that 
they occur in approximately 13% of patients. However, the 
ORBIT-AF study [33] found that they are often subjective 
and many patients who reported them received OACs, 
suggesting that the perceived benefit outweighed the 
potential risk of their use. In the study by Steinberg et al. 
[34] out of 26,684 patients with AF not treated with OAC, 
8,283 (31%) had contraindications related to a high risk 
of bleeding, mainly abnormal blood counts — thrombocy-
topenia, anemia, hemoglobinopathies, neoplasms of the 
hematopoietic system and the lymphatic system (75%) or 
a history of gastrointestinal bleeding (40%). Contraindica-
tions to OAC therapy related to a high risk of bleeding are 
more common in elderly patients with AF. In the study by 
Polo García et al. [35], approximately 20% of patients with 
non-valvular AF did not receive anticoagulation. The main 
reasons were: refusal to monitor coagulation parameters 
by the patient (37.3%), high risk of bleeding (31.1%), uncon-
trolled hypertension (27.9%), and frequent falls (27.6%). In 
a study by Redfors et al. [36], out of 1,300,643 patients, 
43,248 (3.3%) had contraindications to anticoagulant 
therapy and had not received OAC for the last 12 months 
or died in hospital.
The few absolute contraindications for taking OAC inclu-
de active major bleeding (where its source must be iden-
tified and treated), comorbidities (e.g. severe thrombocy-
topenia < 50 platelets/L, severe anemia under diagnosis, 
etc.) or recent high-risk bleeding, such as intracerebral 
hemorrhage (ICH). In such cases, non-pharmacological op-
tions may be considered [2]. The limitations mainly apply to 
older people (over 90 years of age), patients with demen-
tia, after a hemorrhagic stroke or bleeding, with extreme 
kidney and liver failure, and patients with cancer.
Regarding renal failure, none of the randomized trials 
of OAC use included patients with end-stage renal disease. 
Hemodialysis (HD) patients with AF have additional risk 
factors for stroke due to vascular disease, age, diabetes, 
and HD treatment. They are also at increased risk of serio-
us bleeding from uremic platelet dysfunction. Anticoagu-
lation treatment increases the risk of bleeding in patients 
with end-stage renal disease and HD-treated patients up to 
10 times compared to warfarin-treated patients with nor-
mal renal parameters [37]. Arnson et al. [38] conducted an 
analysis assessing the safety of OAC use in patients with 
chronic kidney disease (CKD). The patients enrolled in the 
study were older and had more comorbidities. The group 
with the lowest rates of OAC treatment (27.6%) were pa-
tients with stages 4–5 of chronic renal failure (CRF). The 
use of OAC was associated with a reduced risk of stroke and 
ICH, regardless of the stage of CRF, and a reduced risk of 
death in patients with CRF in stages 1–3. The risk-benefit 
ratio of OAC in advanced CKD is a subject of ongoing de-
bate and clinical consideration.
Patients with hepatic impairment may have a higher 
risk of bleeding with VKAs, while NOACs are associated 
with a lower risk of bleeding complications. In patients 
with a known cause of bleeding, preventive measures 
Table 3. The use of oral anticoagulants (OACs) in patients with atrial fibrillation (AF) at high risk of stroke in clinical trials (based on [20–32])
Study/author When the study was conducted (years) Proportion of patients treated with OA (%)
ORBIT AF II [20] 2011–2014 87
ATRIUM, Meinertz et al. [28] 2009 87
PREFER IN AF [24] 2012–2013 85.6
GARFIELD-AF/Cools et al. [22] 2012–2016 84.3
GLORIA AF II/Huisman et al. [27] 2011–2014 83.2
Chae et al. [29] 2006–2008 82
Krittayaphong et al. [30] 2014–2017 81.6
EORP-AF [23] 2013–2016 About 80
GARFIELD AF/Dalgaard et al. [31] 2010–2016 73.1
Raji et al. [32] 2007 67.8
Cowan et al. [25] 2009–2012 55
Holt et al. [26] 2007–2010 53
Ding et al. [21] 2001–2004 23
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should be taken and OAC therapy initiated as soon as po-
ssible, focusing on the greatest safety profile of the drug. 
Advanced liver disease increases the risk of bleeding 
and affects drug metabolism. Patients with active liver 
disease and AF are often excluded from clinical trials 
with OACs. This group of patients, especially those with 
abnormal blood clotting parameters, may be at greater 
risk of bleeding events. Kuo et al. [39] found, however, 
that in patients with cirrhosis, the benefit of reducing the 
risk of ischemic stroke with NOAC may outweigh the risk 
of bleeding, compared to the lack of treatment, which su-
pports the use of these drugs.
Patients with cancer and AF are a special group in 
which anticoagulant therapy is used with caution. Recent 
analyzes [40, 41] clearly show that NOACs are safe and 
that compared to VKAs, they have fewer thromboembo-
lic and bleeding complications. Vitamin K antagonists 
have a number of disadvantages that may particularly 
interfere with the therapy and treatment of neoplastic 
diseases. These include interactions with chemothera-
py or other medications, food intolerance, and the need 
to stop treatment because of invasive procedures. Im-
portantly, the risk of bleeding may be increased when 
using full doses of NOAC in patients with gastrointesti-
nal neoplasms; therefore, special care should be taken 
in these patients [42].
Summary
Thromboembolism prophylaxis in patients with AF at high 
risk of thromboembolism is an important element of their 
management. Over the years, the profile of the patient de-
scribed as “high-risk patient” has changed. Patients with 
high CHA2DS2-VASc scores always required anticoagulation 
treatment. It should be stated that risk factors, including 
comorbidities, can evolve and therefore the patient sho-
uld be assessed by a physician depending on the specific 
clinical situation. Nevertheless, NOACs are the safest (and 
at the same time available) drugs in reducing the risk of 
thromboembolic complications. These drugs should be 
first considered when implementing anticoagulant therapy. 
There are some limitations, such as severe renal failure, 
liver failure or active cancer, but the latest research shows 
safety in this respect as well.
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